PMID- 31714330
OWN - NLM
STAT- MEDLINE
DCOM- 20200720
LR  - 20211204
IS  - 1558-2035 (Electronic)
IS  - 1558-2027 (Linking)
VI  - 21
IP  - 1
DP  - 2020 Jan
TI  - Effects of sacubutril/valsartan on nutritional status in heart failure with 
      reduced ejection fraction.
PG  - 13-20
LID - 10.2459/JCM.0000000000000895 [doi]
AB  - BACKGROUND: Malnutrition commonly occurs in patients with heart failure with 
      reduced ejection fraction (HFrEF). Sacubitril/valsartan, which is an AT1 
      neprilysin inhibitor, has been shown to reduce mortality and hospitalization in 
      patients with HFrEF. However, its effects on nutritional status remain unclear. 
      METHODS: Sacubitril/valsartan was initiated in 164 symptomatic patients with 
      HFrEF receiving an optimal medical treatment with angiotensin inhibition (mean 
      age: 63 +/- 20 years; 120 males, 60% ischemic cause). The New York Heart 
      Association (NYHA) functional class and nutritional statuses of the patients were 
      evaluated at the switching to AT1 neprilysin inhibitor and at the 6th-month 
      follow-up of the maximum sacubitril/valsartan dose using the geriatric 
      nutritional risk index (GNRI), controlling nutritional status (CONUT) score, 
      prognostic nutritional index (PNI), and prealbumin. RESULTS: After the 
      sacubutril/valsartan treatment, a significant reduction in the number (%) of 
      malnourished patients was observed according to CONUT (before 47% vs. after 7%, 
      P < 0.001), GNRI (before 39% vs. after 19%, P < 0.001), PNI scores (before 36% 
      vs. after 12%, P = 0.002), and prealbumin (before 41% vs. after 12%, P < 0.001). 
      Also significant changes were observed at the baseline and follow-up in the mean 
      scores of the three different nutritional indexes and prealbumin levels [CONUT: 
      2.68 +/- 2.5, 1.02 +/- 1.0 (P < 0.001); GNRI: 97.1 +/- 9.7, 101.2 +/- 5.9 (P < 0.001); 
      PNI: 38.8 +/- 4.8, 41.6 +/- 3.7 (P < 0.001); prealbumin: 14.6 +/- 6.9 mg/dl, 
      17.1 +/- 5.2 mg/dl (P < 0.001)]. Overall, the patients exhibited a significant 
      functional improvement following the initiation of sacubitril/valsartan: 23% of 
      the patients improved by two NYHA classes, 48% improved by one NYHA class, and 
      39% remained stable. CONCLUSION: In patients with HFrEF, the switch from 
      angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy 
      to sacubitril/valsartan resulted in a significant improvement in both nutritional 
      and functional statuses.
FAU - Dereli, Seckin
AU  - Dereli S
AD  - Department of Cardiology, Ordu State Hospital.
FAU - Bayramoglu, Adil
AU  - Bayramoglu A
AD  - Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.
FAU - Kaya, Ahmet
AU  - Kaya A
AD  - Deparment of Cardiology, Ordu University Faculty of Medicine, Ordu, Turkey.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Cardiovasc Med (Hagerstown)
JT  - Journal of cardiovascular medicine (Hagerstown, Md.)
JID - 101259752
RN  - 0 (Aminobutyrates)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Protease Inhibitors)
RN  - 0 (Tetrazoles)
RN  - 80M03YXJ7I (Valsartan)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Aminobutyrates/adverse effects/*therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use
MH  - Biphenyl Compounds
MH  - Drug Combinations
MH  - Drug Substitution
MH  - Female
MH  - Heart Failure/diagnosis/*drug therapy/physiopathology
MH  - Humans
MH  - Male
MH  - Malnutrition/diagnosis/*drug therapy/physiopathology
MH  - Middle Aged
MH  - Neprilysin/antagonists & inhibitors
MH  - Nutrition Assessment
MH  - Nutritional Status/*drug effects
MH  - Prospective Studies
MH  - Protease Inhibitors/adverse effects/*therapeutic use
MH  - Recovery of Function
MH  - Stroke Volume/*drug effects
MH  - Tetrazoles/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Valsartan
MH  - Ventricular Function, Left/*drug effects
EDAT- 2019/11/13 06:00
MHDA- 2020/07/21 06:00
CRDT- 2019/11/13 06:00
PHST- 2019/11/13 06:00 [pubmed]
PHST- 2020/07/21 06:00 [medline]
PHST- 2019/11/13 06:00 [entrez]
AID - 01244665-202001000-00003 [pii]
AID - 10.2459/JCM.0000000000000895 [doi]
PST - ppublish
SO  - J Cardiovasc Med (Hagerstown). 2020 Jan;21(1):13-20. doi: 
      10.2459/JCM.0000000000000895.